Long-lasting tumor response on short-time administration of vemurafenib—A case report

INTRODUCTION Vemurafenib has been approved since 2011 in the United States for the treatment of advanced BRAF V600emutated melanoma as first-line therapy. Although it significantly prolongs overall and progression-free survival, most patients relapse within 6 to 8 months owing to acquisition of drug resistance. New findings suggest that discontinuous dose administration of vemurafenib might prolong response to vemurafenib, but it is unclear whether modified cell signalling or other mechanisms, such as immune-mediated effects, are responsible for this effect.